In order to maximize the synergy between chemotherapy and anti-tumor immune response, Introduction 56 57
By the time a tumor is clinically detectable, it is no longer subject to significant anti-tumor response 58 from the innate and acquired components of the host immune system. Mechanistically, this immune 59 tolerance is the result of complex interactions among tumor cells, T cells, and secreted cytokines [1] . 60 CD8+ effector T cells, also known as cytotoxic T lymphocytes (CTLs), are an important component of the 61
adaptive immune system that responds to tumor antigens and induces cell death. 62
A major barrier to effective CTL response in tumors is suppression by T regulatory cells (Tregs), 63 which inhibit CTL cytotoxic activity via cell-cell contact ( [2] , [3] ) as well as through secreted factors such 64
as TGF-beta ( [4] [5] ). They have posed challenges for cancer immunotherapies as well as preventing the 65 activation of the immune system during more traditional therapy approaches ( [3] , [6] ). Tregs also 66 appear to play a critical role in limiting immune response in maternal tolerance of the fetus and 67 protection of commensal bacteria from the host immune system [2] . 68 Multiple methods have been investigated to break the immune system from tolerance and 69 revive anti-tumor immune activity. The initial focus of these approaches included activation of CTLs 70
through immunostimulatory cytokines such as interleukin-2 (IL-2). More recently, lymphodepleting 71 chemotherapy has been recognized to have paradoxical but important immunostimulatory effects. 72 Heavy lymphodepletion has been reported to enhance the impact of adoptively transferred tumor-73 specific T cells ( [7] ). This leads to the interesting question of whether or not lymphodepletion can also 74 enhance the efficacy of existing T-cell populations to mount an anti-tumor response. While 75
Gemcitabine, 5-Fluorouracil and other cytotoxic drugs can initially suppress immune subpopulations, 76 notably B and T cells, the subsequent proliferation of the immune cells when therapy is completed 77 provides a transient period in which immune response to tumor antigens can be restored. An obvious 78 question then arises: is there a better chemotherapy schedule that could maximize tumor kill and also 79 enhance immune response? 80
To investigate the dynamics of this transient immune response following chemotherapy, we 81 created a mathematical model of the complex tumor-immune dynamics that occur during multiple 82 cycles of chemotherapy. In particular, we investigated three, clinically-relevant, therapeutic dynamics: 83 immunodepletion, immunostimulation via vaccination, and immunosupportive prophylactics. We 84 identified significant immune trade-offs during chemotherapy as well as the relevant patient metrics 85 that determine the magnitude and severity of these compromises. Further, by exploring the impact of 86 clinically-established, as well as more experimental treatment, decisions we illustrate a more complex 87
interplay between chemotherapy and patient immune dynamics than has been previously investigated. 88 Our results indicate that optimal chemotherapy requires identification of a 'Goldilocks Window' in which 89 treatment can both induce cytotoxic effects in the tumor and enhance the immune response to tumor 90 antigens. Therefore, instead of the one-size-fits-all paradigm of fixed therapy regimens, patient immune 91 biology should be a key consideration when developing personalized chemotherapy strategies. 92
Methods

94
Quick guide to equations and assumptions: 95 96 97 98 99 Our model assumes that tumor cells (T) grow unless checked by T effector cells (E). However, effector 100 cells are themselves inhibited by T regulatory cells (R) that are recruited at a rate σ by tumor antigens. 101
This leads to effector-cell-mediated tumor cell death being moderated by the quantity of T regulatory 102 cells ( + ).
Effector cells exhibit different behaviors during immune expansion and immune contraction. 103
This switching behavior is modeled with the Heaviside function ( ( − )). During the immune 104 expansion phase, effector cells are recruited based on both available memory cells (M) and the tumor 105 burden ( + ). Memory cells are the pool of T cells from which effector cells are derived. During 106 immune expansion, the antigenicity of the tumor ( ) induces differentiation to effector cells ( + ). 107
However, as immune tolerance sets in, there is a contraction in the effector T cell population. This is 108 caused by degradation of effector cells by T regulatory cells (1 + + ). During immune contraction, 109 there is also a small influx into the memory T cell compartment due to conversion of effector cells to 110 memory T cells ( ). Finally, the total lymphocyte population is represented by naïve cells (N) which 111 replicate in a logistic growth model (1 − + max ). 112
113
Overall Model Design 114 115
A central assumption of this work is that a clinically-detectable tumor has induced a tolerant 116 state in which the immune system can no longer respond to tumor antigens. Chemotherapy temporarily 117 removes this tolerance through lymphodepletion, which eliminates Tregs and allows a burst of immune 118 response. However, the lymphodepletion itself also kills CTLs and therefore reduces the potential 119 cytotoxic efficacy. This double-edged response to chemotherapy implies that there is an optimal 120 therapeutic strategy. If the dose is too high, then the few remaining immune cells will not be able to 121 take advantage of the tolerance breaking; if the dose is too low, then the immune depletion will be 122 insufficient to break tolerance. In addition to these immune effects, the chemotherapy itself can induce 123 cancer cell death affecting both the tumor size directly and releasing tumor antigens, adding another 124 layer of complexity to the tumor-immune dynamics. 125 We develop a mathematical model that includes five major populations of cells: Tumor cells (T), 126
T effector cells (also known as cytotoxic T lymphocytes, CTLs, and denoted as E), T regulatory 127 cells (Tregs, R), Memory T cells (M), and Naive T cells (N). Immune function is separated into two distinct 128 temporal stages relative to the time of application of each chemotherapy cycle: 1) a period of CTL 129 expansion in a sensitized immune system, immediately following the application of chemotherapy 130 (Figure 1 , panel A), and 2) CTL contraction as tolerance returns (Figure 1, panel B ). The transition 131 between these expansion and contraction phases is governed by mechanisms that remain poorly 132 characterized, but empirically occurs 5-10 days after the expansion starts [8] . In the model, the 133 transition time is set to 5 days after the start of the immune expansion phase. Therefore, there is a 134 window of 5 days immediately following each cycle of chemotherapy in which the immune system is 135 sensitive, and outside of these periods, it is tolerant. 136 6 137 Tumor growth dynamics are approximated via a combination of exponential growth for smaller tumors 159 and power law growth for larger tumors, as shown in the first term on the right hand side of Eq. (1). The 160 transition between these growth dynamics is governed largely by the T * term as defined in equation (2), 161
following the implementation of tumor-immune growth dynamics described in [9] . 162
163
T* employs the method of modeling tumor growth in [9] (specifically the first term on the right 164 hand side of equation 1) by having tumor populations transition from exponential to power law growth. 165
As the authors note, tumors are not able to sustain early exponential growth due to physical and 166 nutrient limitations. A more appropriate model is where there is exponential growth early which then 167 transitions to a power law growth at larger tumor sizes. The size at which this transition in growth occurs 168
is T trans and the smoothness of this transition is governed by the exponent P. The growth term r T 169 represents the growth rate and how aggressively the tumor is developing. 170
The second term of Eq. (1) on the right hand side represents the tumor loss due to killing by 171
CTLs. CTL dynamics are modeled in two phases, expansion (terms 1-3) and contraction (terms 4-6), as 180 described above. Terms 1 and 4 switch between these phases via the Heaviside function, with time t off 181 being the length of the expansion phase (5 days) immediately following each round of chemotherapy. 182 Terms 2 and 3 chiefly govern the growth of CTLs during immune sensitivity to the tumor. CTLs are 183 generated based upon the antigenicity of the tumor (α) as well as the number of tumor and memory T 184 cells. The antigenicity describes how much of an immune response is promoted by the tumor. 185
Modulating this is an amplification rate, γ, since one memory cell can yield multiple effector cells. Term 186 2 represents a moderating term where there is a maximum number of memory and naïve lymphocytes 187 that can be supported by the cytokine pool. This general paradigm of effector cell function being limited 188 by cytokine availability has been supported by lymphodepletion studies that have shown increased CTL 189 activity when IL-7 and IL-15 cytokine-responsive cells were removed. With fewer cytokine sinks, CTL 190 activity was increased [10] . When the immune compartment is full and in homeostasis, this term will be 191 near zero, effectively shutting down CTL recruitment; however, immediately after a dose of 192 chemotherapy, memory and naïve T cells are depleted, which promotes CTL expansion. Term 5 193 represents the contraction of the effector cell compartment that occurs due to immune tolerance. There 194 is a death rate of CTLs, δ E , which is increased by the relative fraction of Tregs that are present, + . Tregs 195
have been shown to inhibit CTLs through a variety of mechanisms, including both depriving cytokines 196 necessary for CTL sustenance as well as direct cytolysis of CTLs [11] . Parameter c represents the 197 suppression efficacy of Tregs. Lastly, term 6 represents the rate of conversion of effector cells back into 198 memory cells, which is an active mechanism during immune contraction [12] . 199 200
Memory T cell dynamics 201 202
203
Memory cells continually replenish themselves through homeostatic growth in term 1. Parameter r M is 204 the maximum memory T-cell growth rate, which is decreased as the memory and naïve cell numbers 205 reach their carrying capacity, K max . During the immune expansion phase (terms 2-4), there is memory cell 206 loss as they are converted to CTLs. The conversion rate is governed in term 4 by the relative abundances 207 of tumor and memory cells, + , as well as the antigenicity, α, as mentioned above. As described in 208
Eq. (3), the rate of recruitment is moderated by the relative homeostasis level of the overall immune 209 system. During the contraction phase, memory cells are replenished from the CTL compartment. A 210 fraction (ω) of the CTL are successfully converted back to memory cells [12] . Due to some loss and 211 inefficiency of conversion, the fraction, ω, is less than the loss from the effector cell compartment, ρ > 0 212 [13] . 213
Regulatory T cell and naïve T cell dynamics 214 215
Tregs are recruited due to secretion of factors such as TGF-beta from peripheral precursor cells by 217 tumor cells with recruitment rate σ, and decay with a rate δ R [14] . 218 219 220
221
Naive T cell dynamics are largely the result of homeostatic proliferation up to a common carrying 222 capacity of K max , which is the maximum number of memory and naïve T cells in the immune system [15] . 223
The naive cell replenishment rate is determined by r N . 224 225
The model was parameterized based on literature sources when possible, as shown in Table 1 . For many 226
cases there was evidence of variation in parameters, as well as no clear study of each individual 227 parameter in our model. This is, in part, due to approach to simplify, mathematically, certain processes 228 in favor of focusing on the tumor-immune dynamics. Where possible, we have tried to make a 229 biologically reasonable order-of-magnitude approximation. In order to address this parameter 230 uncertainty we explicitly consider the impact of parameter variation on model results. Similarly, certain parameters were not succinctly captured in literature studies and were therefore 235 estimated (*). We have addressed the impact of potential parameter variation through sensitivity 236 studies (see Results). 237 238
Simulating chemotherapy and evaluating outcomes 239 240
To establish tolerance in the system and allow transients from initial conditions to dampen before 241 applying therapy, the simulation was started with a tumor size of 10 7 cells. Chemotherapy was started 242 when the tumor reached 10 8 cells and was simulated as periodic doses of cytotoxic therapy at 14 day 243 intervals (a standard cycle length). In total, 10 cycles of chemotherapy were applied. At the time of each 244 treatment cycle, all cell populations (immune and tumor) were instantaneously reduced by a fraction 245
representing the cytotoxic effect of chemotherapy. Immune cells were reduced by the same baseline 246 fraction (C 0 ) on each cycle. To account for tumor resistance to therapy, the fractional tumor reduction 247 for cycle i (C i ) was linearly reduced with each cycle, such that the cytotoxic fraction on the last cycle was 248 75% of C 0 . Approximating the impact of chemoresistance on drug efficacy is challenging since values 249 vary for different classes of drugs. To further complicate resistance impacts, Hao et al. in [16] noted 250 dose-dependent differences between resistant and resensitized prostate cancer cell populations to 251 docetaxel ( Figure 2 , Panel A). The relative advantage of resistant to sensitive cells varied from almost 252 nothing (at very low doses) to a 400% difference. The value of 75% chemotherapy efficacy at resistance 253 represents a 33% advantage of survivorship for a resistant population versus a susceptible population. It 254 is a conservative estimate of the impact of resistance, but we believe it is reasonable given that tumor 255
populations are unlikely to be entirely homogeneously resistant. Varying this range is a relevant 256 question for future research. For our purposes, C i is given by: 257 258
259
The final tumor size after 10 cycles of chemotherapy was compared to the tumor size at the 260 start of treatment (10 8 cells) and evaluated according to RECIST categories. Specifically, a total loss of 261 tumor (<-99% change in size) is a complete response (CR). A change between -30% and -99% is 262 considered a partial response (PR). Tumor changes between -30% and +20% are classified as stable 263 disease (SD) and changes of greater than +20% are seen as progressive disease (PD) [17] . While there 264 are many different methods of measuring therapy efficacy impact on disease, RECIST categories were 265 chosen here since they have correlated well with overall survival in patients across a variety of cancers. 266 267
Simulation environment 268
The model was programmed in the Python language (ver. To analyze the effect of the memory T-cell population on therapy, varying doses of chemotherapy were 278 simulated for a range of memory cell population sizes. The size of the memory T-cell population at the 279 time of therapy was a significant factor affecting the optimal therapeutic response. Memory cell 280 population sizes are variable among patients; Arstila et al. (1999) have estimated there to be 10 6 -10 7 281 memory T cell clones in the human body with approximately 10 5 memory T cells per antigen [9, 18] . 282
However, due to antigen responses being polyclonal, this suggests multiple orders of magnitude of 283 potential variation in memory T-cell numbers. Patient memory-cell numbers influence the maximum 284 chemotherapy dose strength before treatment failure ( Figure 2 ). Generally, there is a minimum 285 memory-cell population size that is necessary for any given strength of chemotherapy to be successful. 286
Above this threshold, the more memory cells there are, the better the improvement with stronger doses 287 of therapy. Conversely, this means that when memory-cell populations are close to the minimum 288 threshold, chemotherapy should be similarly weak if a more favorable treatment outcome is desired. If 289 memory cells are below the minimum threshold, then the optimal strategy is to use strong 290 chemotherapy (Figure 2, panel A and B ). This treatment solely relies on chemotherapeutic cytotoxicity 291 with no immune stimulation. 292 changes in tumor size after therapy versus the initial starting size (10 8 cells). The underlying dynamic 297 reasons for these differences can be seen in the memory populations during low (C) and high dose 298 chemotherapy (D). Low dose chemotherapy allows memory populations (light blue) to be sustained for 299 longer and generate larger CTL responses (green). High dose chemotherapy, however, depletes memory 300 cells faster and leads to declining CTL responses and concurrent tumor escape. 301 302
The double-edged nature of chemotherapy on the immune system can be better understood through 303 the transient dynamics during therapy (Figure 2 , panel C and D). In cases with stronger chemotherapy 304 dosing, there is an early decrease in tumor population levels as the cytotoxic strength of the therapy 305 comes to bear on cancer populations. However, we observe a trend in that these therapies tend to lead 306 to failure and larger final tumor sizes than if treated with a 'weaker' chemotherapy regimen. Weaker 307 chemotherapy regimens exert lower cytotoxic burdens on the tumor but maintain tumor size reduction 308
for the duration of therapy. 309 310
This counterintuitive result stems from the fact that cytotoxicity alone is insufficient for suppressing 311 tumor growth, especially due to the accumulating chemoresistance. Rather, it is the synergistic effect of 312 cytotoxicity as well as the breaking of immune tolerance and consequent recruitment of CTLs that keeps 313 tumor populations in check. Our in silico treatments consistently show that there is an inherent 314 disadvantage to high-dose chemotherapy. There is a gradual decrease in the CTL population over 315 multiple rounds of treatment due to the net loss that stronger dosing causes in memory T-cell 316 populations. It is these memory cells that are affected the most by chemotherapy since they can only 317 recover relatively slowly. If the cytotoxic pressure on memory cells is greater than the recovery rate of 318 that compartment, then even with a resensitized immune system, expansion will lead to fewer CTLs and 319 ultimate treatment failure. In contrast, if the immunodepleting side effects of chemotherapy can be 320 balanced with immune recovery, then more sustainable treatment responses are possible. In short, 321
there is a tradeoff between having chemotherapy strong enough to sufficiently break tolerance, but 322 mild enough to leave sufficient memory T cells for adequate CTL expansion. Akin to the story of 323
Goldilocks and the three bears, the balancing of these two immunological goals leads to an intermediary 324 chemotherapy strength that is 'just right'. In silico simulation shows that this "Goldilocks Window" is 325 highly dependent upon patient-specific, pre-existing memory T-cell populations. 326 327 328
The impact of CTL efficacy 329 330
We sought to identify other relevant patient-specific immune parameters by studying the effect of CTL 331 killing efficacy (k 0 ). With memory-cell sizes set at 10 6 cells, the cytotoxicity rate was varied around the 332 biologically realistic parameter of 0.9 per day [19] . Unsurprisingly, CTL efficacy is a significant 333 determinant of treatment success (Fig. 1 ). Furthermore, CTL efficacy dramatically impacts optimal 334 chemotherapy dosing. Lower rates of CTL-mediated tumor cell death require weaker chemotherapy for 335 more favorable treatment outcomes. As before, the underlying dynamics demonstrate the importance 336 of a large enough memory-cell pool over the course of therapy to supply the CTL pool in sufficient 337 numbers. With a lower value of k 0 , more CTLs are necessary to exert the same degree of immune 338 control over the tumor. This in turn, necessitates a larger pool of memory T cells. Strong chemotherapy 339 on a system with lower k 0 values would prevent sufficient CTL expansion by rapidly diminishing the 340 memory-cell populations. This is counterintuitive since an initial motivation may suggest that, in a 341 situation where a patient has a weaker immune system to combat the cancer, the chemotherapy should 342 be increased in order to compensate. However, our model suggests that the lymphodepleting impact of 343 heavy chemotherapy on an already weaker immune system will only worsen outcomes. 344 345
Impact of tumor growth rates 346 Tumor growth rates are variable, and in the model we used a value of r T = 1000 cell -1 per day, putting 347 growth at a doubling time of 1 day during the fastest exponential growth phase. Experimental and 348 model analyses have shown that selection pressures on growing tumors can lead to significant 349 heterogeneity in metabolism and growth rates [20] . Analysis of the model with different tumor growth 350 rates revealed that optimal dosing was dependent on this variation (Fig. 3 ). For slower growing tumors, 351 greater doses can be used because chemotherapeutic cytotoxicity is sufficient for controlling tumor 352 growth. For faster growing tumors (larger r T ) it becomes necessary to decrease chemotherapeutic 353 strength in order to achieve optimal outcomes; chemotherapeutic cytotoxicity is insufficient alone and 354 so CTL-mediated tumor death is necessary. Greater CTL involvement, though, imposes the same trade-355 off as above, in that dosing must be weakened in order to sustain memory cell populations. Importantly, 356
for the most aggressively growing tumors, there is actually a 'worst-case scenario' of intermediary 357 chemotherapy strength. Here, the worst chemotherapy is not, in fact, the strongest possible dose and is 358 instead a 'mid-range' strength in treatment. At this chemotherapeutic strength, the drug alone is 359 insufficient to cause a reduction in tumor size. However, the dose is still strong enough to lead to severe 360 memory cell population depletion and undermines any immune efforts at constraining tumor growth. 361
These considerations demonstrate how the tumor growth rate is a primary determinant of tumor 362 control and, depending on the individual patient's tumor, determines which dynamics are capable of 363 leading to successful treatment responses. 364 365 Figure 3 : Treatment outcomes for variation in CTL efficacy (A and B) and tumor growth rate (C and D). 366
Panels A and C represent RECIST outcomes. Red is progressive disease (PD), dark blue is complete 367 response (CR), light blue is partial response (PR) and yellow is stable disease (SD). As CTLs become more 368 efficient at killing tumor cells, there is a dramatic reduction in final tumor size and a significant 369 improvement in outcome. However, below a threshold efficacy, chemotherapy has a much more 370 important role in impacting the role of therapy. Weaker chemotherapy leads to better outcomes. A 371 similar pattern is shown in response to variation in tumor growth rates. Faster growing tumors lead to 372 significantly poorer treatment outcomes. This trend is most observable when, for chemotherapy values 373 below 0.4, the range of tumor growth rates and CTL efficacies where tumor reduction is possible 374 significantly increases. Chemotherapy plays an important modulating role in these faster growing 375 tumors, however, with optimal treatment coming from weaker chemotherapy. 376 377
In short, patient immune biology determines optimal chemotherapy strength by determining which 378 immune dynamics can be taken advantage of to control tumor growth. Low dose therapy is optimal in 379 situations where the patient immune response is robust enough to control tumor growth. This requires 380 both a sufficient memory-cell population as well as sufficiently high efficacy in CTL cytotoxicity. In 381 contrast, high-dose chemotherapy is optimal to control tumor growth when either the immune system 382 is unable to generate a sufficient CTL response, or when the tumor is slow-growing. However, in many 383 situations where the immune system is able to enhance the effect of chemotherapy, dosing must be 384 moderated so that it does not impose an overly large recovery burden and impede immune effects. 385 386
Improvements to therapy outcomes from immunostimulatory vaccines: The Goldilocks Window 387 388
Patient-specific vaccines have become a recent hallmark in personalized cancer therapy. One of the first 389 to acquire FDA approval was Sipuleucel-T, for treating metastatic castrate resistant prostate cancer [21] . 390
Each vaccine is tailored to a specific patient by culturing dendritic cells from patient serum samples 391
(taken roughly 72 hours before vaccine administration). The goal is to activate dendritic cells in vitro 392 with a specific tumor protein target. These cultured antigen-presenting cells are then injected into the 393 patient in order to stimulate an antitumor immune response. Three doses were administered in 2 week 394 intervals with significant clinical responses being observed. Vaccination led to a 22% reduction in the 395 relative risk of death, although there was no noticeable decrease in the rate of progression of disease 396 [21] . The specific effect on T cells has been quantified by looking at T-cell receptor changes in response 397
to vaccination. Subjects that received the vaccine saw a change in abundance and diversity of T-cell 398 receptors in tumor-infiltrating lymphocytes. Certain receptor sequences were enriched, while others 399 were significantly decreased [22] , suggesting that the vaccine promoted an antigen-specific immune 400 response against the tumor. 401
To study the effects and potential synergy of chemotherapy with this method of T-cell stimulation, we 402 simulated a vaccine regime similar to that used for Sipuleucel-T (3 doses, spaced 14 days apart), with 403 different vaccine strengths. Mathematically decays with a half-life, t half , of 3 days, a biologically realistic timespan in line with the short half-lives of 410 dendritic cells [23] . This model of dynamic antigenicity can be expanded for multiple vaccinations, as 411 used in the clinical protocol (eq. 10). 412
Here, H(t) is again the Heavyside function. n vac represents the total number of vaccine injections and t n 414
represents the time of the n th vaccination. 415
The ODEs used for the simulation of immune and tumor cell populations are then dependent on the 416 instantaneous current value of α v (t) throughout the course of simulated therapy. 417
Under this scheme, results show that vaccine therapy can improve outcomes, but only within a specific 418 range of chemotherapy strengths (Fig. 4) . For very high chemotherapy doses, the beneficial effects of a 419 vaccine are diminished. As before, the underlying cause for decreasing efficacy is the persistent 420 lymphodepletion of memory cells due to the chemotherapy. Antigenicity augmentation due to vaccine 421 stimulation is offset by reduced CTL expansion. However, very low-dose chemotherapy poses its own 422 challenges, because with insufficient lymphodepletion, tolerogenic mechanisms and greater Treg 423 recruitment inhibit any CTL response augmented by the vaccine. The immune system remains closer to  424 tumor-tolerized homeostasis, and as a result vaccine stimulation is mitigated because the immune 425 system is already suppressed. 426 427 428 Figure 4 : Improvements in tumor reduction due to vaccine application. Panel A shows the RECIST 429 responses achieved for different vaccine strengths and chemotherapy strengths with black being the 430 non-vaccine baseline. Vaccine strengths (v) are 1 (blue), 10 (green), 100 (red), 1000 (light blue). Larger 431 vaccine strengths lead to more successful RECIST responses for stronger chemotherapy doses. When 432 looking at the absolute number of improvement in cellular reduction (B), a window of optimal 433 chemotherapy ranges appears. Only when chemotherapy is in this range can vaccines provide a 434 significant additional benefit. 435 436 437
Therefore, there exists an optimal dosing window for chemotherapy, a "Goldilocks" window. 438
Quantitatively, we define this window to be the region in which a therapy dose can offer at least a 20% 439 reduction in tumor size since this is the necessary amount for disease to become classified as a partial 440 response. In order for there to be this maximized benefit from vaccine application, the chemotherapy 441 regimen must be 'just right'. Chemotherapy must have sufficient lymphodepletion to resensitize the 442 immune system, but must leave enough immune cells such that vaccine stimulation leads to a large CTL 443
response. Similar to the results of chemotherapy without the vaccine, the specific range of this 444
Goldilocks window depends upon the initial patient memory cell (M 0 ) numbers (not shown). More 445 memory cells mean a system able to tolerate a larger dose of chemotherapy and still lead to a large 446 vaccine-triggered CTL response. In contrast, fewer memory cells requires weaker chemotherapy doses 447
to derive a maximum benefit from vaccine administration. 448 449
Impact of variation in immune support 450 451
Chemotherapeutic lymphodepletion in the clinical setting can pose a serious threat to the safety of the 452 patient through neutropenia [24] , which commonly leads to dose reductions and disruptions to the 453 standard schedule of therapy for patients. Consequently, multiple tools have been developed to help 454 mitigate the effects of chemotherapy on the immune system. For example, it was recognized that 455 dexamethasone treatment before carboplatin and gemcitabine could not only increase chemotherapy 456 efficacy but also reduce the lymphodepleting effects by preventing uptake in the spleen and bone 457 marrow [25] . In contrast, other aspects of cancer therapy can potentially hamper CTL responses to 458 tumor insults. For example, G-CSF application has been shown to reduce CD8 + T cell activation and could 459
conceivably impede the impact of lymphodepletion as a break from immune tolerance [26] . More 460 generally, however, the broader impact of immune system augmentation or suppression during therapy 461 remains unexamined. 462
In order to examine the effect of attenuated or augmented lymphodepletion on therapy outcome, we 463 allowed for variable chemotherapeutic toxicity to immune populations, as compared to the tumor 464 population. Mathematically, this simply means modifying the chemotherapy dose by a scaling factor h. 465 The effect of chemotherapy on immune cell populations at a given treatment time is: 466 467
where I 1 is the immunological population size after application of chemotherapy, I 0 is the population size 468 before therapy, and 0 < C < 1 is the dose strength. The specific numerical range in which h falls 469
represents either attenuated or augmented chemotherapeutic toxicity. For values of 0 < h < 1, this 470
represents an attenuated toxicity relative to the toxicity on the tumor. In contrast, values of h > 1 471 represent higher toxicity on patient immune populations than on the tumor. This could be due to 472 patient-dependent increased sensitivity to chemotherapy. However, this is really beyond the scope of 473 our model, especially since mathematically I 1 could become negative. This is clearly an area where our 474 model may not accurately capture the dynamics. Therefore, we have restricted hC such that hC < 1. For 475 our in silico therapies, h was varied across these ranges where I 1 > 0 for three different strengths of 476 treatment. Values of C were chosen to represent lower (C= 0.25), middle (C= 0.6), and higher (C = 0.9) 477 dose chemotherapy. 478
Outcomes of therapy due to variation in h depended upon the strength of chemotherapy. 479
Interestingly, the results suggest that immune-supporting combination therapy has essentially no 480 benefit when given with low dose chemotherapy. As shown in Figure 5 , similar tumor reduction 481 occurred for a wide range of values of h around h=1 (which represents no immune support). 482 Furthermore, outcomes were worse when h was very low or very high. In situations where it was very 483 low, final tumor sizes were large because a lack of lymphodepletion did not sufficiently break immune 484 tolerance. In contrast, for larger h values, there was over-depletion which prevented an effective T-cell 485 response despite significant tolerance breaking. 486 In contrast, high dose chemotherapy saw treatment failure or success highly dependent upon 487 the amount of immune support. Similar to low dose therapy, a small value of h that mitigated the 488 depleting effects of chemotherapy led to the best possible outcomes in terms of tumor shrinkage. Final 489 tumor sizes were, in fact, multiple orders of magnitude lower than was possible with low-dose 490 chemotherapy. As h increased (representing less toxicity mitigation) treatment outcomes rapidly 491
worsened. The transition value h*, where the clinical outcome rapidly shifts, indicates a threshold effect 492 with regard to immune support. For high chemotherapy doses, immune support treatments must have a 493 significantly large mitigation (h < h*) of immunodepletion in order for successful treatment responses to 494 occur. 495
Interestingly, the moderate strength chemotherapy regimen yielded only partial benefits of 496 either extreme. The greatest tumor reduction possible, with immune support, yielded tumors that were 497 smaller than those achievable with low dose chemotherapy. However, these tumors were still multiple 498 orders of magnitude larger than those achievable with high dose chemotherapy. For treatment failure at 499 lower immune support (h > h*) tumor sizes were actually larger than when high dose chemotherapy 500 failed. 501
Clinically, the results suggest that chemotherapy dose strength can be used to mitigate 502 uncertainty regarding the amount of immune support a certain treatment will give to a specific patient. 503
Low dose therapy offers a wide range of potential immune support in which treatment can successfully 504 reduce tumor sizes. The disadvantage is that the maximum tumor size reduction still leaves larger 505 tumors than are possible using higher doses of chemotherapy. While our model has not analyzed this, a 506 potential impact is that larger tumor sizes could lead to more heterogeneous populations and thus lead 507 to a higher likelihood of resistant or metastatic populations. However, higher doses have a narrower 508 range of immune support in which they are successful. Chemotherapy can be balanced, then, against 509
how certain the clinician is of the benefit that G-CSF (or other immune supporting drug) will give. For 510 patients where there is high certainty of a significant benefit due to the drug, high dose therapy is 511 optimal. In contrast, lower dosing should be used when the drug may have lower or variable efficacy. 512 513
Variable Immune Support and Impacts on Observed Cohort Responses 514 515
Finally, we sought to investigate how variation in the effectiveness of these immune adjuvants 516 might impact treatment outcomes in a group of patients. Chemotherapy treatment leads to a wide 517 range of responses, both successful and unsuccessful, across multiple types of cancer [17] . This variation 518 has been attributed to both disease variation, patient variation, and interactions between the two. 519
However, less attention has been given to variable patient responses to secondary drugs -such as G-CSF 520 -and how they impact therapy. Patient responses to these secondary drugs are currently poorly 521 measured and could have significant implications for therapy outcomes. 522
To better explore the effect of variable patient responses to immune support drugs, cohorts of 523 500 patients were randomly generated from a normal distribution with a mean immune support 524 response value of h = 0.8 and variance of 0.2. These values were chosen to center the distribution 525 around the model-derived threshold value h* = 0.8. Similar to our previous investigations, cohorts were 526 then subjected to regimens of low (C = 0.4) and high (C = 0.8) chemotherapy strengths. Percent changes 527 in tumor size after therapy were displayed for each individual patient in the cohort to generate a 528 waterfall plot. In doing so, we used our model to simulate cohort responses as is commonly measured in 529 aggregated studies of patient data [17] . The waterfall plots (Fig. 5 ) illustrate that chemotherapy strength 530 can significantly change the proportion of successfully responding patients in a population with variable 531 responses to immune prophylactics. This is significant since the proportion of successful responses is 532 often an important criterion for judging therapeutic efficacy. The simulated waterfall plots show how 533 clinical outcomes could not only be the result of therapy, but also due to inherent immune variation 534 within the cohort. 535 536 537 The asterisk denotes that simulations were only run up to this h value for the highest dose 541 chemotherapy. (B) Cohorts are treated with these differing regimes of high and low chemotherapy, 542 showing significant differences in the proportion of successful versus unsuccessful responders. 543 544
Discussion
545
A major barrier to success for immunotherapy in cancer is tolerogenic mechanisms that reduce the 546 immune response to tumor antigens ( [27] , [3] , [6] ) . A potential solution has come from observations 547 that lymphodepletion stimulates homeostatic proliferation in the immune system which can transiently 548 restore immune response. This has led to increasing efforts to selectively apply chemotherapy to 549 improve outcomes from immunotherapy [28] . 550 551
To better understand this potential synergy, we constructed a mathematical model to frame these 552 complex dynamics and identify critical parameters that govern the clinical outcomes. Our studies 553 focused on three clinically-observed dynamics of immunodepletion, immunostimulatory vaccination, 554
and immunosupportive prophylactics. With regard to immunodepletion, we demonstrated that 555 chemotherapy results in a trade-off. At very high doses, chemotherapy has a maximal cytotoxic effect on 556 the tumor but also maximally depletes memory T cells such that no effective CTL response can be 557 mounted despite the transient loss of tolerance during re-expansion of the immune cells after 558 completion of chemotherapy. Similarly, low doses of chemotherapy are insufficient to produce the post-559 treatment immune cell expansion that is necessary for reversal of immune tolerance. 560
Importantly, however, we find there is a "Goldilocks" range of chemotherapy doses in which 561 lymphodepletion causes adequate immune resensitization, but does not impose an overly large 562 recovery burden. This window is governed by the patient-specific quantity of memory T cells so that 563 larger pre-treatment T-cell populations allow more favorable outcomes with higher doses of 564 chemotherapy. In contrast, fewer pretreatment CTLs can limit the immune response even in the 565 "Goldilocks" range of chemotherapy. Thus, there is a necessary 'minimum efficacy' of effector cells for 566 successful stimulation of immune response by chemotherapy. Below this threshold of immune activity, 567
the benefit of chemotherapy is almost solely dependent on its inherent cytotoxicity ( Fig. 6 ) 568 569 Figure 6 : A diagram explaining tumor outcomes at varying chemotherapy strengths and immune support 570
doses. If therapy is too weak, then immune stimulation cannot be maximally effective and direct 571 chemotherapy-mediated tumor cell death is also low. This yields a suboptimal tumor reduction. When 572 chemotherapy is too strong, there may be more tumor cell death due to the drug, but insufficient 573 immune activation due to over depletion of T cells. There is a moderate dose, however, that represents 574 a Goldilocks window of maximizing both T-cell activation as well as drug-induced tumor cell death. This 575 range of dosing provides at least a 20% reduction in tumor size (relative to the initial tumor size of 10 8 576 cells). 577 578
Our model also provides insight into the potential effects of variation in the tumor growth rate. In 579 slower growing tumors, chemotherapy alone can be sufficient to achieve optimal treatment response. 580
Treatment of faster growing tumors, however, is best when the chemotherapy is administered to 581 enhance the immune response. Unfortunately, if the pre-treatment population of CTLs is small, we find 582 chemotherapy for rapidly growing tumors will be ineffective if it is both highly lymphodepleting and 583 insufficiently cytotoxic to significantly reduce tumor growth. Assessing the clinical importance of this 584 question is challenging because it remains unclear from the literature as to the actual size of the 585 population of tumor-specific T cells that are present during treatment. In spite of these difficulties, the 586 impact and existence of anti-tumor immunity has been bolstered by recent immunotherapies which act 587
to remove inhibitions to T-cell action [29] . 588 589
Chemotherapy is increasingly being used in concert with vaccines to help stimulate the patient immune 590 system. We investigated the interactions between vaccines and lymphodepletion and found that, as 591 before, there is a window of chemotherapy ranges in which vaccines can improve outcomes versus 592 chemotherapy alone. At very high doses, however, the resulting lymphodepletion substantially reduces 593 benefits of immune stimulation by vaccination. More broadly, other novel immunotherapies could also 594 potentially be hampered by over-depletion of the immune system. 595 596
To further investigate the potential impact of this interaction, we modeled the effect of differential 597 responses to immune prophylactics. G-CSF and other drugs have become common recourses in 598
